Examination of osteoporosis treatment continuation rate in outpatient clinic 3rd report: With for the Corona era

Abstract

The treatment continuation rates in patients started on osteoporosis treatment for the first time before (pre-pandemic group) and during (pandemic group) the coronavirus disease 2019 (COVID-19) pandemic were compared, to evaluate the effect of the COVID-19 pandemic on osteoporosis treatment continuation. There was no difference in the prescription rates by physicians of the various available therapeutic agents between the two groups. The osteoporosis drug continuation rate was higher, although the difference was not significant, in the pandemic group. Therapeutic interventions by osteoporosis liaison managers/others and thorough infection control allowed the patients to continue their osteoporosis treatment even during the COVID-19 pandemic.